Table 5.

Unadjusted and multivariable-adjusteda logistic regression analyses of the associations between higher ALb measure 2c and unfavorable breast cancer clinicopathologic characteristics among 229 Black breast cancer survivors in the Women's Circle of Health Follow-Up Study (2014–2018) with both AL measures computed.

AL measure 1 cohortd (n = 229)
UnadjustedMultivariable-adjusted
OR (95% CI)OR (95% CI)
Tumor behavior: invasive (stage I, II, and III) vs. noninvasive (stage 0 or DCIS)
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)
  Higher (4–8)1.01 (0.53–1.90)1.23 (0.63–2.41)
P = 0.99P = 0.55
Tumor grade: poorly differentiated vs. well and moderately differentiated
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)
  Higher (4–8)1.63 (0.95–2.79)2.10 (1.16–3.81)
P = 0.08P = 0.01
Tumor size: ≥2 cm vs. <2 cm
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)
  Higher (4–8)1.22 (0.71–2.11)1.37 (0.76–2.46)
P = 0.48P = 0.30
ER status: ER vs. ER+
 AL
  Lower (0–3)1.00 (referent)1.00 (referent)
  Higher (4–8)1.14 (0.62–2.09)1.07 (0.56–2.02)
P = 0.68P = 0.84
  • Note: Bold values indicate statistical significance.

  • aThe following covariates were included in the multivariable-adjusted regression analyses: (i) age at diagnosis; (ii) birthplace; (iii) marital status; (iv) menopausal status; (v) family history of breast cancer.

  • bThe median AL score among Women's Circle of Health Follow-Up Study participants was 3. Thus, 3 was used as the cutoff point to dichotomize the AL variable.

  • cAL measure 2 was computed on the basis of the following biomarkers: SBP, DBP, waist circumference, glucose level, albumin, eGFR, BMI, and use of medication to control hypertension, hypercholesterolemia, or diabetes.

  • dAL measure 1 cohort (n = 229) included Women's Circle of Health Follow-Up Study participants with biomarkers contributing to AL measure 1 computation (SBP, DBP, waist circumference, glucose level, HDL, triglycerides, total cholesterol and/or LDL, and use of medication to control hypertension, hypercholesterolemia, or diabetes) and AL measure 2 computation as described above.